In pediatric ALL, more samples and relevant experimental data are needed to explore whether deletion of the CDKN2A/B or the encoded locus is related to resistance to TKIs in BCR-ABL1-positive patients, and may be able to guide the selection of targeted therapies for BCR-ABL1 positive pediatric ALL patients. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.